Prognostic significance of β2-adrenergic receptor expression in malignant melanoma.
Recent studies cite β2-adrenergic receptor (β2AR) antagonists as novel therapeutic agents for melanoma, as they may reduce the disease progression. The β2AR has shown to be expressed in malignant melanoma. However, it remains unclear whether the β2AR expression has a clinical and pathological significance in patients with cutaneous malignant melanoma. We herein conducted a clinicopathological study to investigate the protein expression of β2AR in malignant melanoma of the skin and its prognostic significance. One hundred thirty-three patients with surgically resected cutaneous malignant melanoma were evaluated. Tumor sections were stained by immunohistochemistry for β2AR, Ki-67, the microvessel density (MVD) determined by CD34, and p53. β2AR was highly expressed in 44.4 % (59 out of 133) of the patients. The expression of β2AR was significantly associated with the tumor thickness, ulceration, T factor, N factor, disease stage, tumor size, cell proliferation (Ki-67), and MVD (CD34). Using Spearman's rank test, the β2AR expression was correlated with Ki-67 (r = 0.278; 95 % CI, 0.108 to 0.432; P = 0.001), CD34 (r = 0.445; 95 %CI, 0.293 to 0.575; P < 0.001), and the tumor size (r = 0.226; 95 % CI, 0.053 to 0.386; P = 0.008). Using a univariate analysis, the tumor thickness, ulceration, disease stage, β2AR, Ki-67, and CD34 had a significant relationship with the overall and progression-free survivals. A multivariable analysis confirmed that β2AR was an independent prognostic factor for predicting a poor overall survival (HR 1.730; 95 % CI 1.221-2.515) and progression-free survival (HR 1.576; 95 % CI 1.176-2.143) of malignant melanoma of the skin. β2AR can serve as a promising prognostic factor for predicting a worse outcome after surgical treatment and may play an important role in the development and aggressiveness of malignant melanoma.
['Shimizu|Akira|A|', 'Kaira|Kyoichi|K|', 'Mori|Keita|K|', 'Kato|Madoka|M|', 'Shimizu|Kimihiro|K|', 'Yasuda|Masahito|M|', 'Takahashi|Ayumi|A|', 'Oyama|Tetsunari|T|', 'Asao|Takayuki|T|', 'Ishikawa|Osamu|O|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D014408:Biomarkers, Tumor D049109:Cell Proliferation D005260:Female D015870:Gene Expression D015972:Gene Expression Regulation, Neoplastic D006801:Humans D007150:Immunohistochemistry D053208:Kaplan-Meier Estimate D008297:Male D008545:Melanoma D008875:Middle Aged D009367:Neoplasm Staging D011379:Prognosis D018343:Receptors, Adrenergic, beta-2 D047368:Tumor Burden
β2-Adrenergic receptor Melanoma Cutaneous Immunohistochemistry Prognostic factor Angiogenesis